NYSE$HCA
HCA Holdings Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
HCA Healthcare's financial performance was positive, demonstrating strong demand and effective execution of strategic plans.
HCA Healthcare reported strong second-quarter results with revenues of $17.492 billion and net income of $1.461 billion, or $5.53 per diluted share. The company's performance reflected strong demand for its services and effective execution of its strategic plan. HCA Healthcare also raised its 2024 guidance.
- Revenues totaled $17.492 billion.
- Net income attributable to HCA Healthcare, Inc. totaled $1.461 billion, or $5.53 per diluted share.
- Adjusted EBITDA totaled $3.550 billion.
- Cash flows from operating activities totaled $1.971 billion.
Headline financials
Revenue & EPS history
HCA · Revenue · Quarterly
$17.5B
Forward guidance
HCA Healthcare revised its 2024 estimated guidance ranges issued on January 30, 2024.
Tailwinds
- Revenues: $69.750 to $71.750 billion
- Net Income Attributable to HCA Healthcare, Inc.: $5.675 to $5.975 billion
- Adjusted EBITDA: $13.750 to $14.250 billion
- EPS (diluted): $21.60 to $22.80 per diluted share
- Capital expenditures for 2024, excluding acquisitions, are estimated to be in the range of $5.1 to $5.3 billion.
Headwinds
- The Company’s revised 2024 guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding patient volumes and payor mix as well as general economic conditions, including inflation.
- Excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.
- The Company’s guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks.
- Changes in revenues due to declining patient volumes
- Potential increased expenses related to labor, supply chain or other expenditures
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.1%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+2.9%
Avg return
30 days after
47%
31 / 66 earnings
Positive
+16.1%
Q2 2020
Best reaction
-21.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.2% | -8.3% | -16.8% | |
| Q4 2025 | +6.2% | +3.4% | +11.3% | |
| Q3 2025 | +1.5% | +6.4% | +11.6% | |
| Q2 2025 | +0.8% | +3.1% | +3.8% | |
| Q1 2025 | -4.0% | +1.1% | +10.3% | |
| Q4 2024 | -3.8% | +0.7% | -2.7% | |
| Q3 2024 | -10.6% | -9.5% | -18.5% | |
| Q2 2024 | +5.7% | +9.0% | +17.7% | |
| Q1 2024 | -0.9% | -1.5% | +1.5% | |
| Q4 2023 | +6.3% | +7.9% | +8.7% | |
| Q3 2023 | -6.5% | -6.5% | +5.0% | |
| Q2 2023 | -3.2% | -2.9% | -3.2% | |
| Q1 2023 | +5.7% | +2.7% | +4.3% | |
| Q4 2022 | -0.6% | +2.6% | -2.2% | |
| Q3 2022 | +0.8% | +4.3% | +10.3% | |
| Q2 2022 | +9.6% | +12.9% | +18.6% | |
| Q1 2022 | -21.9% | -21.2% | -24.0% | |
| Q4 2021 | -1.4% | -1.1% | +5.5% | |
| Q3 2021 | -7.0% | -5.6% | -8.1% | |
| Q2 2021 | +14.5% | +14.2% | +13.3% | |
| Q1 2021 | +2.5% | +0.7% | +4.5% | |
| Q4 2020 | +3.7% | +5.9% | +5.6% | |
| Q3 2020 | -4.4% | -9.3% | +12.5% | |
| Q2 2020 | +16.1% | +14.6% | +21.2% | |
| Q1 2020 | -5.4% | -2.4% | -2.2% | |
| Q4 2019 | +2.6% | -2.0% | -10.1% | |
| Q3 2019 | +6.2% | +5.3% | +10.3% | |
| Q2 2019 | -8.7% | -13.0% | -17.4% | |
| Q1 2019 | -1.1% | +0.2% | -2.3% | |
| Q4 2018 | +5.6% | +6.1% | +5.5% | |
| Q3 2018 | +3.5% | +4.2% | +12.0% | |
| Q2 2018 | +14.9% | +14.7% | +21.4% | |
| Q1 2018 | +2.1% | +1.9% | +7.7% | |
| Q4 2017 | +3.6% | +2.1% | +1.9% | |
| Q3 2017 | +0.9% | +0.3% | +11.6% | |
| Q2 2017 | -5.2% | -6.6% | -7.9% | |
| Q1 2017 | -1.2% | -0.4% | -0.1% | |
| Q4 2016 | +3.4% | +5.7% | +10.2% | |
| Q3 2016 | -2.1% | -4.5% | -9.6% | |
| Q2 2016 | -1.1% | -3.8% | -4.8% | |
| Q1 2016 | -1.7% | — | — | |
| Q4 2015 | +3.1% | — | — | |
| Q3 2015 | -0.1% | — | — | |
| Q2 2015 | -2.8% | — | — | |
| Q1 2015 | -1.2% | — | — | |
| Q4 2014 | -1.7% | — | — | |
| Q3 2014 | -2.1% | — | — | |
| Q2 2014 | +4.1% | — | — | |
| Q1 2014 | -1.2% | — | — | |
| Q4 2013 | -1.0% | — | — | |
| Q3 2013 | -5.1% | — | — | |
| Q2 2013 | +0.1% | — | — | |
| Q1 2013 | +3.8% | — | — | |
| Q4 2012 | -1.1% | — | — | |
| Q3 2012 | +8.0% | — | — | |
| Q2 2012 | +1.1% | — | — | |
| Q1 2012 | -1.1% | — | — | |
| Q4 2009 | +3.5% | — | — | |
| Q4 2011 | +3.5% | — | — | |
| Q3 2011 | +2.6% | — | — | |
| Q3 2010 | +2.6% | — | — | |
| Q2 2011 | -20.6% | — | — | |
| Q2 2010 | -20.6% | — | — | |
| Q1 2011 | -0.2% | — | — | |
| Q1 2010 | -0.2% | — | — | |
| Q4 2010 | -0.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro